Results 171 to 180 of about 36,344 (217)
Acyclovir Therapy for Mucocutaneous Herpes Simplex Infections in Immunocompromised Patients.
Lancet, The, 1981 11 of 24 immunocompromised patients with mucocutaneous herpes simplex virus (HSV) infections were given intravenous acyclovir in a randomised double-blind placebo-controlled study. Patients receiving acyclovir experienced no major adverse effects.
Bonnie Bean, B Bean, C D Mitchell
exaly +4 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Southern Medical Journal, 1983
Acyclovir, the new virucidal drug recently approved by the Food and Drug Administration for the treatment of herpes simplex virus (HSV), is the first available effective drug to treat such infections. Acyclovir boasts activity against four of the five major herpes-group viruses, including herpes simplex (types 1 and 2), varicella-zoster, and Epstein ...
T M, Appelboom, F P, Flowers
+9 more sources
Acyclovir, the new virucidal drug recently approved by the Food and Drug Administration for the treatment of herpes simplex virus (HSV), is the first available effective drug to treat such infections. Acyclovir boasts activity against four of the five major herpes-group viruses, including herpes simplex (types 1 and 2), varicella-zoster, and Epstein ...
T M, Appelboom, F P, Flowers
+9 more sources
Archives of Internal Medicine, 1984
Acyclovir is a selective antiherpes agent. Its selective activity is by exploitation of differences between the herpes-specific and host cell enzymes. The major route of elimination of acyclovir is via the kidney by glomerular filtration and renal tubular secretion.
Z, Mechl, B, Sopková
+10 more sources
Acyclovir is a selective antiherpes agent. Its selective activity is by exploitation of differences between the herpes-specific and host cell enzymes. The major route of elimination of acyclovir is via the kidney by glomerular filtration and renal tubular secretion.
Z, Mechl, B, Sopková
+10 more sources
Infection Control, 1986
In recent years there have been great advances made in antiviral therapy. One of the most promising of the new agents to be introduced is acyclovir. This antiviral, which selectively inhibits the replication of particular DNA viruses, is being used clinically in the treatment and prevention of viral infections caused by several of the herpes viruses ...
C A, Zabrosky, G, Milkovich
openaire +2 more sources
In recent years there have been great advances made in antiviral therapy. One of the most promising of the new agents to be introduced is acyclovir. This antiviral, which selectively inhibits the replication of particular DNA viruses, is being used clinically in the treatment and prevention of viral infections caused by several of the herpes viruses ...
C A, Zabrosky, G, Milkovich
openaire +2 more sources
New England Journal of Medicine, 1992
REPORTS of the clinical efficacy of acyclovir, a selective and specific inhibitor of herpesvirus replication, appeared in the literature a decade ago.
Alastair J.J. Wood +2 more
openaire +2 more sources
REPORTS of the clinical efficacy of acyclovir, a selective and specific inhibitor of herpesvirus replication, appeared in the literature a decade ago.
Alastair J.J. Wood +2 more
openaire +2 more sources
Journal of Antimicrobial Chemotherapy, 1983
Acyclovir given intravenously in either low dose (5 mg/kg every 8 h) or high dose (500 mg/m2 every 8 h) significantly reduced pain and accelerated skin healing in acute herpes zoster occurring in otherwise healthy adults. The higher dose also significantly reduced the duration of viral shedding. No significant effect on post-herpetic neuralgia could be
B, Bean, D, Aeppli, H H, Balfour
openaire +2 more sources
Acyclovir given intravenously in either low dose (5 mg/kg every 8 h) or high dose (500 mg/m2 every 8 h) significantly reduced pain and accelerated skin healing in acute herpes zoster occurring in otherwise healthy adults. The higher dose also significantly reduced the duration of viral shedding. No significant effect on post-herpetic neuralgia could be
B, Bean, D, Aeppli, H H, Balfour
openaire +2 more sources
Scandinavian Journal of Infectious Diseases, 1988
Acyclovir crystals in the urine of a 28-year-old woman are described. The patient received intravenous acyclovir for herpes encephalitis. The crystalluria was accompanied by impairment of the renal tubules as evidenced by increased urinary beta-2-microglobulin excretion. Consecutive series of 60 patients on oral acyclovir and 20 patients on intravenous
N A, Peterslund, M L, Larsen, H, Mygind
openaire +2 more sources
Acyclovir crystals in the urine of a 28-year-old woman are described. The patient received intravenous acyclovir for herpes encephalitis. The crystalluria was accompanied by impairment of the renal tubules as evidenced by increased urinary beta-2-microglobulin excretion. Consecutive series of 60 patients on oral acyclovir and 20 patients on intravenous
N A, Peterslund, M L, Larsen, H, Mygind
openaire +2 more sources
2000
Abstract Acyclovir is a synthetic purine nucleoside analog widely used in the treatment of Herpes simplex and Varicella zoster virus infections. It blocks replication by inhibiting viral DNA synthesis. Before inhibition can occur, acyclovir must be phosphorylated by viral thymidine kinase; the affinity for viral thymidine kinase is ...
openaire +1 more source
Abstract Acyclovir is a synthetic purine nucleoside analog widely used in the treatment of Herpes simplex and Varicella zoster virus infections. It blocks replication by inhibiting viral DNA synthesis. Before inhibition can occur, acyclovir must be phosphorylated by viral thymidine kinase; the affinity for viral thymidine kinase is ...
openaire +1 more source